6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
| Image |  |
|---|---|
| Description | scientific article published on 11 June 2013 |
| Author/s |
author: Thomas Bachelot Nicole Tubiana Mathieu Xavier Pivot Bruno Coudert |
| Publication date | June 11, 2013 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |